Who Paid My Doc
Joel Silver
Hartford, CT Medical Doctor
NPI 1013976299 CMS profile 1013
43 Woodland St, Suite G-80, Gothic Park, Hartford, CT 06105
General payments
$57,260
Research payments
$0
Ownership & investment interest
$54,000
Through program year 2025, Joel Silver of Hartford, CT is reported in the CMS Open Payments database as having received $57,260 across 186 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $54,000 across 10 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $43 | 2 | |
| 2024 | General | $1,154 | 3 | |
| 2023 | General | $24,200 | 11 | |
| 2022 | General | $95 | 1 | |
| 2021 | General | $8,872 | 8 | |
| 2020 | General | $17,165 | 36 | |
| 2019 | General | $5,731 | 125 | |
| 2024 | Ownership | $9,000 | 2 | |
| 2023 | Ownership | $9,000 | 2 | |
| 2022 | Ownership | $9,000 | 2 | |
| 2021 | Ownership | $9,000 | 2 | |
| 2020 | Ownership | $9,000 | 1 | |
| 2019 | Ownership | $9,000 | 1 |
Beside peers
- Joel Silver
- Connecticut median
- Middle half of Connecticut
- National median
In program year 2025, general payments to Joel Silver were reported at $43. Among 12,665 Connecticut profiles paid that year, the median was $167 and the middle half received between $54 and $639.
Show as a table
| Year | Joel Silver | Connecticut median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,731 | $163 | $50–$671 | $163 |
| 2020 | $17,165 | $111 | $33–$382 | $114 |
| 2021 | $8,872 | $124 | $39–$443 | $132 |
| 2022 | $95 | $138 | $45–$535 | $149 |
| 2023 | $24,200 | $148 | $47–$556 | $160 |
| 2024 | $1,154 | $157 | $49–$599 | $164 |
| 2025 | $43 | $167 | $54–$639 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 46 drugsPart D claims
1,321
Drug cost
$6,446,488
Branded share of claims
41%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Pomalyst Pomalidomide | Brand | 53 | $1,212,430 | |
| Revlimid Lenalidomide | Brand | 47 | $795,841 | |
| Brukinsa Zanubrutinib | Brand | 35 | $611,167 | |
| Xtandi Enzalutamide | Brand | 27 | $518,819 | |
| Xpovio Selinexor | Brand | 15 | $416,306 | |
| Imbruvica Ibrutinib | Brand | 33 | $403,594 | |
| Ibrance Palbociclib | Brand | 27 | $373,955 | |
| Lenalidomide | Generic | 35 | $342,499 | |
| Calquence Acalabrutinib Maleate | Brand | 19 | $282,071 | |
| Lenvima Lenvatinib Mesylate | Brand | 11 | $272,138 |
The 10 drugs with the highest cost, of 46 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 93 billing codesPaid by Medicare
$1,897,611
Medicare patients
313
Services billed
82,308
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 43% | |
| Chronic kidney disease | 36% | |
| Diabetes | 35% | |
| Ischemic heart disease | 30% | |
| Cancer | 26% | |
| Heart failure | 25% | |
| Atrial fibrillation | 25% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, denosumab, 1 mg J0897 | Office | 16 | 4,560 | $93,617 |
| Injection, ferric derisomaltose, 10 mg J1437 | Office | 16 | 2,400 | $37,527 |
| Injection, epoetin alfa, biosimilar, (retacrit) (for non-esrd use), 1000 units Q5106 | Office | 11 | 4,440 | $25,885 |
| Injection, zoledronic acid, 1 mg J3489 | Office | 14 | 125 | $605 |
| Injection, hydrocortisone sodium succinate, up to 100 mg J1720 | Office | 17 | 24 | $358 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 14 | 1,550 | $141 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| RYBREVANT |
|
$44 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
186 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.